The advantages of CAR‐T therapies are recognizing specific surface antigen, activating T cells in an MHC‐unrestricted manner, long‐term in vivo persistence and proliferation, and efficient homing of CAR‐T cells to the tumour site, which are believed to be a potential method to eliminate CSCs. The gene discussed is HLA-C; the disease is neoplasm.